PMID- 9779299
OWN - NLM
STAT- MEDLINE
DCOM- 19981209
LR  - 20220409
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 16
IP  - 5
DP  - 1998 Sep-Oct
TI  - Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate 
      with clinical disease activity in rheumatoid arthritis.
PG  - 533-40
AB  - OBJECTIVE: Plasmin and matrix metalloproteinase-3 (MMP-3) have been linked to 
      articular destruction in rheumatoid arthritis (RA). We compared circulating 
      levels of plasmin-mediated fibrin degradation product (FDP D-dimer) and MMP-3 
      with traditional parameters of disease activity in RA to determine their clinical 
      utility. MATERIALS AND METHODS: Serum levels of MMP-3 and D-dimer were determined 
      by enzyme-linked immunoassays in 60 patients with RA. Twenty healthy females and 
      21 patients with systemic lupus erythematosus (SLE) served as controls. RESULTS: 
      MMP-3 (436.8 +/- 474.2 ng/ml) and D-dimer levels (351.2 +/- 296.3 ng/ml) were 
      markedly elevated in the sera from RA patients as compared with healthy controls 
      (43.9 +/- 15.2 ng/ml and 63.0 +/- 64.1 ng/ml, p < 0.0001, respectively). Both 
      levels strongly correlated with each other (r = 0.627, p < 0.0001) and were 
      closely associated with various clinical parameters for the disease activity of 
      RA, including the erythrocyte sedimentation rate (ESR) and the Lansbury's 
      activity index (p < 0.0001). MMP-3 levels were more highly correlated with 
      articular parameters such as the swollen and painful joint counts (r = 0.454, p = 
      0.0002), whereas D-dimer levels correlated well with C-reactive protein (CRP) 
      levels (r = 0.581, p < 0.0001). In SLE patients, MMP-3 (239.1 +/- 199.6 ng/ml, p 
      < 0.0001) and D-dimer levels (86.9 +/- 85.2 ng/ml, p = 0.0278) were also higher 
      than in healthy controls. Both levels correlated with each other (r = 0.612, p = 
      0.0025), and were associated with ESR and CRP levels, as was observed in RA 
      patients, but not with most of the other clinical indicators for SLE. 
      CONCLUSIONS: Serum levels of MMP-3 and D-dimer are clinically useful indicators 
      for disease activity in RA. Our results further support the hypothesis that MMP-3 
      and plasmin may interact in the inflammatory synovial tissues, and thus augment 
      the articular destruction seen in RA. In SLE patients, however, MMP-3 producing 
      cells could be different from in RA patients, and further studies will be 
      required to clarify the pathogenetic mechanism underlying the raised serum levels 
      of MMP-3 and/or D-dimer.
FAU - Ichikawa, Y
AU  - Ichikawa Y
AD  - Department of Internal Medicine 4, Tokai University School of Medicine, Kanagawa, 
      Japan.
FAU - Yamada, C
AU  - Yamada C
FAU - Horiki, T
AU  - Horiki T
FAU - Hoshina, Y
AU  - Hoshina Y
FAU - Uchiyama, M
AU  - Uchiyama M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (fibrin fragment D)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antifibrinolytic Agents/*blood
MH  - Arthritis, Rheumatoid/*blood/*physiopathology
MH  - Biomarkers
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*analysis
MH  - Humans
MH  - Lupus Erythematosus, Systemic/blood/physiopathology
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Severity of Illness Index
EDAT- 1998/10/21 00:00
MHDA- 1998/10/21 00:01
CRDT- 1998/10/21 00:00
PHST- 1998/10/21 00:00 [pubmed]
PHST- 1998/10/21 00:01 [medline]
PHST- 1998/10/21 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1998 Sep-Oct;16(5):533-40.